ZAI LAB LIMITED - AMER

Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting

08 Nov 2022 08:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer

08 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Participation in November Investor Conferences

31 Oct 2022 07:52:02 By Nasdaq GlobeNewswire

Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022

18 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Launches its first Trust Report

14 Oct 2022 07:55:00 By Nasdaq GlobeNewswire

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

27 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

20 Sep 2022 08:03:00 By Nasdaq GlobeNewswire

Zai Lab Announces Participation in September Investor Conferences

23 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

09 Aug 2022 16:05:01 By Nasdaq GlobeNewswire

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

08 Aug 2022 07:02:07 By Nasdaq GlobeNewswire

Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022

19 Jul 2022 07:38:43 By Nasdaq GlobeNewswire

Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs

17 Jul 2022 20:00:00 By Nasdaq GlobeNewswire

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis

13 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited

27 Jun 2022 00:00:00 By Nasdaq GlobeNewswire

Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

10 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

03 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference

31 May 2022 08:00:02 By Nasdaq GlobeNewswire

Zai Lab Announces Upcoming Presentations at June Investor Conferences

24 May 2022 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022

20 May 2022 16:01:00 By Nasdaq GlobeNewswire

Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates

10 May 2022 16:01:01 By Nasdaq GlobeNewswire